Piramal Pharma Solutions (PPS) announced that its Grangemouth, UK facility has completed production of its 1,500th antibody-drug conjugate (ADC) batch. The milestone batch represents a commercial oncology product.
The Grangemouth site serves as Piramal’s dedicated bioconjugate development and manufacturing facility, supporting projects from early-stage development through commercial production. The site is integrated within Piramal’s global network as part of its ADCelerate program, which supports rapid transition of ADC projects from research to GMP manufacturing.
PPS began working on ADCs more than two decades ago and was among the first contract development and manufacturing organizations (CDMOs) to receive U.S. FDA approval for commercial ADC production. The company reports that the Grangemouth facility has produced hundreds of distinct bioconjugates for clinical, commercial, and non-GMP purposes over that time.
The site maintains U.S. FDA and UK Medicines and Healthcare products Regulatory Agency (MHRA) accreditations. According to Piramal, the accomplishment reinforces its long-term activity in the ADC manufacturing space and its continued investment in bioconjugate capabilities.